Skip to main content

Measuring meaningful change in lupus clinical trials

Edited by: Matthew Liang and Chan-Bum Choi

This series of articles has not been sponsored. All articles have undergone the journal’s standard peer review process overseen by the Series Editors, with final decisions made by the Editors-in-Chief. The Series Editors and Editors-in-Chief declare no competing interests.

  1. Since the 2002 Dusseldorf meeting, one new agent, Benlysta, has been approved by the US Food and Drug Administration for systemic lupus erythematosus. Experiences from the field in conducting trials of all the...

    Authors: Chan-Bum Choi, Matthew H. Liang and Sang-Cheol Bae
    Citation: Arthritis Research & Therapy 2016 18:1
  2. Measuring lupus disease activity accurately remains a challenging and demanding task given the complex multi-system nature of lupus, an illness known for its variability between patients and within the same pa...

    Authors: Jamal Mikdashi and Ola Nived
    Citation: Arthritis Research & Therapy 2015 17:183
  3. A minimal clinically important difference (MCID) is an important concept used to determine whether a medical intervention improves perceived outcomes in patients. Prior to the introduction of the concept in 19...

    Authors: Sharan K Rai, Jinoos Yazdany, Paul R Fortin and J Antonio Aviña-Zubieta
    Citation: Arthritis Research & Therapy 2015 17:143
  4. Systemic lupus erythematosus (SLE) is a systemic autoimmune disease with diverse manifestations. Although the approval of new therapies includes only one agent in 50 years, a number of promising new drugs are ...

    Authors: Kristin M Corapi, Mary Anne Dooley and William F Pendergraft III
    Citation: Arthritis Research & Therapy 2015 17:110